Similarly, for the antiviral group, patients with AST ≤ 1× ULN had significantly lower percentage of abnormal AFP levels compared to those with AST > 1× ULN in CHB, cirrhosis, and early-stage HCC subgroups (4.0% vs. 21.8%, p < 0.001; 5.5% vs. 32.7%, p < 0.001; and 48.4% vs. 64.5%, p = 0.004, respectively). This evidence concerns the gene AFP and hepatocellular carcinoma.